|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2009-9-17
|
|
pubmed:abstractText |
Dynorphin A (Dyn A) is an endogenous ligand for kappa opioid receptors. To restrict the conformational mobility, we synthesized several cyclic Dyn A-(1-11)NH(2) analogues on solid phase utilizing ring-closing metathesis (RCM) between the side chains of allylglycine (AllGly) residues incorporated in positions 2, 5, and/or 8. Cyclizations between the side chains of AllGly gave reasonable yields (56-74%) of all of the desired cyclic peptides. Both the cis and trans isomers were obtained for all of the cyclic peptides, with the ratio of cis to trans isomers depending on the position and stereochemistry of the AllGly. Most of the cyclic Dyn A-(1-11)NH(2) analogues examined exhibit low nanomolar binding affinity for kappa opioid receptors (K(i) = 0.84-11 nM). In two of the three cases, the configuration of the double bond has a significant influence on the opioid receptor affinities and agonist potency. All of the peptides inhibited adenylyl cyclase activity in a concentration-dependent manner with full or close to full agonist activity. These potent Dyn A analogues are the first ones cyclized by RCM.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-10963903,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-10987958,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-11301048,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-11352717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-14711314,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-15787962,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-15999987,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-16277299,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-16496038,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-1674217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-17315860,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-17539621,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-17868902,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-18338852,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-18412318,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-1972964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-2156363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-2875731,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-3024707,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-4202581,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-5443684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-6118870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-6327549,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-7001627,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-7608905,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-7948735,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-7966152,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-8096246,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-8676350,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-9111295,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-9316689,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19715279-9456002
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1520-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
24
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5619-25
|
|
pubmed:dateRevised |
2011-8-25
|
|
pubmed:meshHeading |
pubmed-meshheading:19715279-Adenylate Cyclase,
pubmed-meshheading:19715279-Amino Acid Sequence,
pubmed-meshheading:19715279-Animals,
pubmed-meshheading:19715279-CHO Cells,
pubmed-meshheading:19715279-Cricetinae,
pubmed-meshheading:19715279-Cricetulus,
pubmed-meshheading:19715279-Cyclization,
pubmed-meshheading:19715279-Drug Design,
pubmed-meshheading:19715279-Dynorphins,
pubmed-meshheading:19715279-Molecular Sequence Data,
pubmed-meshheading:19715279-Rats,
pubmed-meshheading:19715279-Receptors, Opioid, kappa,
pubmed-meshheading:19715279-Stereoisomerism,
pubmed-meshheading:19715279-Substrate Specificity
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Design, synthesis, and pharmacological activities of dynorphin A analogues cyclized by ring-closing metathesis.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
